we want to
give patients
more than a
fighting chance
against cancer. We want to
restore lives, once and for all.

ABOUT ONCOLYZE

We are Oncolyze, a pre-clinical stage biopharmaceutical company that is developing a class of therapeutics to treat cancer in a new and disruptive way.

What may just sound like a cool name indeed carries a greater meaning. Our name is actually derived from the combination of ‘onco’ meaning cancer and ‘lyze’ referring to lysis, rupture or ‘popping’ of a cellular membrane. A complex name is just that, a name, because on the contrary, we actually leverage quite a simple mechanism of action to selectively target, lyse (pop) and kill mature cancer cells and cancer stem cells, while sparing normal cells.

Our lead drug candidate, OM-301, is a fusion peptide with two components. One part attaches to a specific molecule found almost exclusively on the surface of cancer cells (more than 80% of cancer types we have studied); the other drills holes in the cell membrane. That’s it. Simple, selective and rapid destruction of cancer cells at their surface, without ever needing to get inside and manipulate cellular machinery.

SOUNDS INTERESTING? LEARN MORE
ABOUT THE SCIENCE BEHIND ONCOLYZE.

As an early stage biotech, we have to pick our battles wisely, and treating cancer has turned out to be a perennial war. Our leadership team and scientific collaborators have decided to focus on acute myelogenous leukemia (AML). Unfortunately, AML patients have a dismal 25% chance for 5-year survival. This is largely because the currently available therapies are unable to adequately destroy the leukemia stem cells. As a result, even patients that see an apparent remission eventually relapse, in some cases within one year.

So why AML? Well, we have overwhelming preclinical evidence in a mouse model of AML that OM-301 can destroy leukemic stem cells. Such data suggest that it may be able to disrupt the current standard of care and deliver dramatic benefit to these patients, while also providing hope for patients suffering from countless other hematologic and solid cancers.

AML IS A DEVASTATING, ORPHAN CONDITION.
LEARN MORE ABOUT HOW WE ARE TRYING TO TREAT AML
Hands icon

Our leadership team blends
entrepreneurial passion with
broad life science experience
across discovery, development
and commercialization

LEADERSHIP

  • Steven J. Evans

    Steven J. Evans, MD

    Founder & Chief Executive Officer
  • Alex Stojanovic, PhD

    Alex Stojanovic, PhD

    Chief Operating Officer
  • Larry Altstiel MD, PhD

    Larry Altstiel MD, PhD

    Chief Scientific Officer
  • Barbara A. Carlin CPA, MBA

    Barbara A. Carlin CPA, MBA

    CHIEF FINANCIAL OFFICER
Diploma icon

Our team is guided by An
accomplished board with extensive
experience in building, growing and
leading life science companies

BOARD OF DIRECTORS

  • Steven J. Evans

    Steven J. Evans, MD

    Founder & Chief Executive Officer
  • John H Abeles, MD

    John H Abeles, MD

    FOUNDER
  • Alexander Zukiwski, MD

    Alexander Zukiwski, MD

    Clinical Advisor
  • Rosemary Mazanet, MD, PHD

    Rosemary Mazanet, MD, PHD

    Clinical Advisor
Books icon

Oncolyze is advised by some of the
world’s most respected thought
leaders in leukemia research and
therapeutic development

ADVISORS

  • Daniel Von Hoff, MD, FACP, FASCO, FAACR

    Daniel Von Hoff, MD, FACP, FASCO, FAACR

    Director, Scientific Advisory Board
  • Matthew Pincus, MD, PhD

    Matthew Pincus, MD, PhD

    Inventor & Chief Scientific Advisor
  • Michael Andreeff, MD, PhD

    Michael Andreeff, MD, PhD

    Scientific Advisory Board
  • Martin Tallman, MD

    Martin Tallman, MD

    Scientific Advisory Board
  • William Haseltine, PhD

    William Haseltine, PhD

    Director, Business Advisory Board
  • Guido Marcucci, MD

    Guido Marcucci, MD

    SCIENTIFIC ADVISORY BOARD